FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212902023> ?p ?o ?g. }

• W3212902023 endingPage "e003134" @default.
• W3212902023 startingPage "e003134" @default.
• W3212902023 abstract "Patients with cancer benefit from treatment with immune checkpoint inhibitors (ICIs), and those with an inflamed tumor microenvironment (TME) and/or high tumor mutation burden (TMB), particularly, tend to respond to ICIs; however, some patients fail, whereas others acquire resistance after initial response despite the inflamed TME and/or high TMB. We assessed the detailed biological mechanisms of resistance to ICIs such as programmed death 1 and/or cytotoxic T-lymphocyte-associated protein 4 blockade therapies using clinical samples.We established four pairs of autologous tumor cell lines and tumor-infiltrating lymphocytes (TILs) from patients with melanoma treated with ICIs. These tumor cell lines and TILs were subjected to comprehensive analyses and in vitro functional assays. We assessed tumor volume and TILs in vivo mouse models to validate identified mechanism. Furthermore, we analyzed additional clinical samples from another large melanoma cohort.Two patients were super-responders, and the others acquired resistance: the first patient had a non-inflamed TME and acquired resistance due to the loss of the beta-2 microglobulin gene, and the other acquired resistance despite having inflamed TME and extremely high TMB which are reportedly predictive biomarkers. Tumor cell line and paired TIL analyses showed high CD155, TIGIT ligand, and TIGIT expression in the tumor cell line and tumor-infiltrating T cells, respectively. TIGIT blockade or CD155-deletion activated T cells in a functional assay using an autologous cell line and paired TILs from this patient. CD155 expression increased in surviving tumor cells after coculturing with TILs from a responder, which suppressed TIGIT+ T-cell activation. Consistently, TIGIT blockade or CD155-deletion could aid in overcoming resistance to ICIs in vivo mouse models. In clinical samples, CD155 was related to resistance to ICIs in patients with melanoma with an inflamed TME, including both primary and acquired resistance.The TIGIT/CD155 axis mediates resistance to ICIs in patients with melanoma with an inflamed TME, promoting the development of TIGIT blockade therapies in such patients with cancer." @default.
• W3212902023 created "2021-11-22" @default.
• W3212902023 creator A5004693750 @default.
• W3212902023 creator A5005482539 @default.
• W3212902023 creator A5012922874 @default.
• W3212902023 creator A5014499294 @default.
• W3212902023 creator A5019488402 @default.
• W3212902023 creator A5019984630 @default.
• W3212902023 creator A5032033606 @default.
• W3212902023 creator A5033326805 @default.
• W3212902023 creator A5033862426 @default.
• W3212902023 creator A5039970331 @default.
• W3212902023 creator A5044697200 @default.
• W3212902023 creator A5045307530 @default.
• W3212902023 creator A5048960816 @default.
• W3212902023 creator A5057090026 @default.
• W3212902023 creator A5062065307 @default.
• W3212902023 creator A5074950427 @default.
• W3212902023 creator A5075803724 @default.
• W3212902023 creator A5079163477 @default.
• W3212902023 creator A5082720782 @default.
• W3212902023 creator A5090501626 @default.
• W3212902023 creator A5090560513 @default.
• W3212902023 date "2021-11-18" @default.
• W3212902023 modified "2023-10-17" @default.
• W3212902023 title "TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment" @default.
• W3212902023 cites W1910012553 @default.
• W3212902023 cites W2004630197 @default.
• W3212902023 cites W2029399624 @default.
• W3212902023 cites W2039123767 @default.
• W3212902023 cites W2046972425 @default.
• W3212902023 cites W2049553585 @default.
• W3212902023 cites W2050457398 @default.
• W3212902023 cites W2066671159 @default.
• W3212902023 cites W2079018735 @default.
• W3212902023 cites W2082252308 @default.
• W3212902023 cites W2097995306 @default.
• W3212902023 cites W2104885590 @default.
• W3212902023 cites W2107556275 @default.
• W3212902023 cites W2124427232 @default.
• W3212902023 cites W2130410032 @default.
• W3212902023 cites W2141575268 @default.
• W3212902023 cites W2142169541 @default.
• W3212902023 cites W2143772132 @default.
• W3212902023 cites W2160834915 @default.
• W3212902023 cites W2225828937 @default.
• W3212902023 cites W2292383635 @default.
• W3212902023 cites W2329974159 @default.
• W3212902023 cites W2340636398 @default.
• W3212902023 cites W2465860350 @default.
• W3212902023 cites W2557336488 @default.
• W3212902023 cites W2560367415 @default.
• W3212902023 cites W2587048937 @default.
• W3212902023 cites W2757936530 @default.
• W3212902023 cites W2783897381 @default.
• W3212902023 cites W2793629403 @default.
• W3212902023 cites W2801787974 @default.
• W3212902023 cites W2884495860 @default.
• W3212902023 cites W2897283341 @default.
• W3212902023 cites W2914903153 @default.
• W3212902023 cites W2944181742 @default.
• W3212902023 cites W2975736685 @default.
• W3212902023 cites W2976744492 @default.
• W3212902023 cites W2999613850 @default.
• W3212902023 cites W3003788535 @default.
• W3212902023 cites W3006007810 @default.
• W3212902023 cites W3013199660 @default.
• W3212902023 cites W3015205417 @default.
• W3212902023 cites W3019679892 @default.
• W3212902023 cites W3031115858 @default.
• W3212902023 cites W3037669104 @default.
• W3212902023 cites W3043661095 @default.
• W3212902023 cites W3082149473 @default.
• W3212902023 cites W3084404519 @default.
• W3212902023 cites W3086117981 @default.
• W3212902023 cites W3125964008 @default.
• W3212902023 cites W3169974561 @default.
• W3212902023 doi "https://doi.org/10.1136/jitc-2021-003134" @default.
• W3212902023 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8603290" @default.
• W3212902023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34795004" @default.
• W3212902023 hasPublicationYear "2021" @default.
• W3212902023 type Work @default.
• W3212902023 sameAs 3212902023 @default.
• W3212902023 citedByCount "27" @default.
• W3212902023 countsByYear W32129020232022 @default.
• W3212902023 countsByYear W32129020232023 @default.
• W3212902023 crossrefType "journal-article" @default.
• W3212902023 hasAuthorship W3212902023A5004693750 @default.
• W3212902023 hasAuthorship W3212902023A5005482539 @default.
• W3212902023 hasAuthorship W3212902023A5012922874 @default.
• W3212902023 hasAuthorship W3212902023A5014499294 @default.
• W3212902023 hasAuthorship W3212902023A5019488402 @default.
• W3212902023 hasAuthorship W3212902023A5019984630 @default.
• W3212902023 hasAuthorship W3212902023A5032033606 @default.
• W3212902023 hasAuthorship W3212902023A5033326805 @default.
• W3212902023 hasAuthorship W3212902023A5033862426 @default.
• W3212902023 hasAuthorship W3212902023A5039970331 @default.
• W3212902023 hasAuthorship W3212902023A5044697200 @default.

• next